Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Malcolm

Showing results (361-370 of 388) with videos related to

Pageof 39
Sort By:
Plos Genetics|November 13, 2012
Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel SyndromeTomoo Ogi, Sarah Walker, Tom Stiff, et al.
The American Journal of Pathology|July 24, 2003
Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasiasJane Starczynski, William Simmons, Joanne R Flavell, et al.
Journal of Biological Engineering|July 28, 2009
Solving a Hamiltonian Path Problem with a bacterial computerJordan Baumgardner, Karen Acker, Oyinade Adefuye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancerE L Mayer, D Trapani, S-E Kim, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cellsB A Malcolm, R Liu, F Lahser, et al.
Annals of Neurology|December 15, 2018
Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasiaKatherine Schon, Nienke J H van Os, Nicholas Oscroft, et al.
Cell|February 11, 2009
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damageGrant S Stewart, Stephanie Panier, Kelly Townsend, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Journal of Biological Engineering|May 22, 2008
Engineering bacteria to solve the Burnt Pancake ProblemKarmella A Haynes, Marian L Broderick, Adam D Brown, et al.
Cell Stem Cell|August 20, 2019
Distinct Molecular Trajectories Converge to Induce Naive PluripotencyHannah T Stuart, Giuliano G Stirparo, Tim Lohoff, et al.
Pageof 39

Showing results (361-370 of 388) with videos related to

Sort By:
Pageof 39
Plos Genetics|November 13, 2012
Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel SyndromeTomoo Ogi, Sarah Walker, Tom Stiff, et al.
The American Journal of Pathology|July 24, 2003
Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasiasJane Starczynski, William Simmons, Joanne R Flavell, et al.
Journal of Biological Engineering|July 28, 2009
Solving a Hamiltonian Path Problem with a bacterial computerJordan Baumgardner, Karen Acker, Oyinade Adefuye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancerE L Mayer, D Trapani, S-E Kim, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cellsB A Malcolm, R Liu, F Lahser, et al.
Annals of Neurology|December 15, 2018
Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasiaKatherine Schon, Nienke J H van Os, Nicholas Oscroft, et al.
Cell|February 11, 2009
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damageGrant S Stewart, Stephanie Panier, Kelly Townsend, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Journal of Biological Engineering|May 22, 2008
Engineering bacteria to solve the Burnt Pancake ProblemKarmella A Haynes, Marian L Broderick, Adam D Brown, et al.
Cell Stem Cell|August 20, 2019
Distinct Molecular Trajectories Converge to Induce Naive PluripotencyHannah T Stuart, Giuliano G Stirparo, Tim Lohoff, et al.
Pageof 39